Scarica l'app Stockscreener
15.51
0.19%
0.03
Dopo l'orario di chiusura:
15.59
0.08
+0.52%
Precedente Chiudi:
$15.48
Aprire:
$15.22
Volume 24 ore:
1.17M
Relative Volume:
1.03
Capitalizzazione di mercato:
$1.60B
Reddito:
$83.98M
Utile/perdita netta:
$-264.46M
Rapporto P/E:
-5.0985
EPS:
-3.0421
Flusso di cassa netto:
$-263.47M
1 W Prestazione:
-0.13%
1M Prestazione:
-1.90%
6M Prestazione:
+70.81%
1 anno Prestazione:
+36.29%
Intervallo 1D:
$15.00
$15.65
Intervallo di 1 settimana:
$14.41
$16.22
Portata 52W:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
15.51 | 1.60B | 83.98M | -264.46M | -263.47M | -3.0421 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Revenue Check: What is the next catalyst for Nurix Therapeutics Inc2026 Trading Volume Trends & Technical Entry and Exit Tips - baoquankhu1.vn
A Look At Nurix Therapeutics (NRIX) Valuation After Strong 1 Year Return And High Price To Sales Ratio - finance.yahoo.com
NRIX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NRIX Technical Analysis & Stock Price Forecast - Intellectia AI
Nurix Therapeutics chief legal officer Ring sells $124k in stock - au.investing.com
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Nurix (NRIX) legal chief sells 8,148 shares under 10b5-1 plan - Stock Titan
8,148-Share Rule 144 Notice for NRIX (NASDAQ: NRIX) - Stock Titan
Institution Moves: What is the next catalyst for Nurix Therapeutics IncPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - MSN
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 10%What's Next? - MarketBeat
Liquidity Mapping Around (NRIX) Price Events - Stock Traders Daily
Nurix Therapeutics (NRIX) moves 6.9% higher: Will this strength last? - MSN
Nurix Therapeutics : 2026 Proxy Statement vF (20260327) - marketscreener.com
Vanguard disaggregates holdings; Nurix (NRIX) beneficial ownership shown as 0% - Stock Titan
Aug Closing: Will Nurix Therapeutics Inc announce a stock splitWeekly Investment Recap & Verified Entry Point Detection - baoquankhu1.vn
Bexobrutideg data and cash position anchor Nurix (NASDAQ: NRIX) 2026 proxy - Stock Titan
Aug Breakouts: What is the long term forecast for Nurix Therapeutics Inc stockM&A Rumor & Risk Managed Investment Signals - baoquankhu1.vn
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last? - Yahoo Finance
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 10.9%Time to Buy? - marketbeat.com
Winners Losers: Is Nurix Therapeutics Inc a stock for growth or value investors2026 Key Highlights & Trade Opportunity Analysis - baoquankhu1.vn
Retail Trends: Is Nurix Therapeutics Inc forming a bullish divergence2026 Snapshot & Technical Confirmation Trade Alerts - baoquankhu1.vn
Nurix Therapeutics (NASDAQ:NRIX) Given Buy Rating at HC Wainwright - MarketBeat
NRIX Stock: HC Wainwright & Co. Reiterates Buy Rating with $32 T - GuruFocus
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - The Manila Times
Nurix Therapeutics announces presentations showcasing depth of research pipeline and scientific leadership at the American Association for Cancer Research (AACR) annual meeting - marketscreener.com
Nurix Therapeutics Announces Presentations Showcasing Depth Of Research Pipeline And Scientific Leadership At The American Association For Cancer Research (AACR) Annual Meeting - TradingView
Nurix Therapeutics plans oral presentation on multiple degrader programs at San Diego conference - Traders Union
Cancer meeting to feature 5 Nurix studies, including brain tumor data - Stock Titan
Why (NRIX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - AOL.com
Nurix Therapeutics hits 80-plus relative strength rating benchmark - MSN
Investment Recap: Is Nurix Therapeutics Inc undervalued by DCF analysisGap Up & Low Drawdown Trading Techniques - baoquankhu1.vn
Stocks to watch: Nurix Therapeutics sees relative strength rating jump to 83 - MSN
Cinctive Capital Management LP Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Short Squeeze: Can Nurix Therapeutics Inc grow without external fundingWeekly Stock Summary & Community Verified Trade Signals - baoquankhu1.vn
Nurix Therapeutics, Inc. $NRIX Stake Cut by Commodore Capital LP - MarketBeat
Nurix Therapeutics clears key benchmark, hitting 80-plus RS rating - MSN
Gains Report: Should I buy Nurix Therapeutics Inc stock now2026 Short Interest & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Surprises Report: Can Oak Woods Acquisition Corporation Equity Right disrupt its industry2026 Snapshot & Pattern Based Trade Signal System - baoquankhu1.vn
A Look At Nurix Therapeutics (NRIX) Valuation After Expanded Equity Distribution Agreement - Sahm
Understanding Momentum Shifts in (NRIX) - Stock Traders Daily
Market Moves: Will Nurix Therapeutics Inc announce a stock splitPortfolio Value Summary & Verified Technical Trade Signals - baoquankhu1.vn
Rhenman & Partners Asset Management AB Purchases 162,500 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Can Nurix Therapeutics Inc scale operations efficiently2025 Earnings Impact & Stepwise Trade Signal Guides - baoquankhu1.vn
Nurix Therapeutics Expands ATM Equity Offering Capacity - The Globe and Mail
Is Nurix Therapeutics Inc. stock a top momentum playJuly 2025 Levels & Scalable Portfolio Growth Ideas - Naître et grandir
Nurix Therapeutics amends equity distribution agreement for $413.65 million stock offering - Investing.com India
Nurix Therapeutics adds $413.65M at-the-market equity facility with Piper Sandler - TradingView
Inflation Data: Whats the RSI of Nurix Therapeutics Inc stockPortfolio Value Report & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):